Rahbari Rezgar, Moradi Nariman, Abdi Mohammad
Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Department of Clinical Biochemistry, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Clin Chim Acta. 2021 May;516:1-7. doi: 10.1016/j.cca.2021.01.011. Epub 2021 Jan 21.
The COVID-19 pandemic remains a significant problem involving health systems worldwide. Accurate and early detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is critical for minimizing spread and initiating treatment. Among test methods, real-time reverse-transcriptase polymerase-chain-reaction (rRT-PCR) is considered the gold standard. Although this test has high specificity and relatively high sensitivity, the occurrence of falsely negative results in symptomatic patients and/or having a positive CT scan remains a challenge. Sources of error can be pre-analytical (sampling, storage and processing), analytical (RNA extraction, cDNA synthesis and amplification) and post-analytical (interpretation and analysis and test reporting). These potential sources of error and efforts to mitigate are reviewed in this article with an emphasis on the analytical phase.
新冠疫情仍是一个涉及全球卫生系统的重大问题。准确、早期检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染对于减少传播和启动治疗至关重要。在检测方法中,实时逆转录聚合酶链反应(rRT-PCR)被视为金标准。尽管该检测具有高特异性和相对较高的灵敏度,但有症状患者和/或CT扫描呈阳性者出现假阴性结果的情况仍然是一项挑战。误差来源可能是分析前(采样、储存和处理)、分析中(RNA提取、cDNA合成和扩增)以及分析后(解读、分析和检测报告)。本文对这些潜在误差来源及缓解措施进行了综述,重点在于分析阶段。